Production (Stage)
Solid Biosciences Inc.
SLDB
$2.81
-$0.08-2.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 30.91M | 96.43M | -- | -- | 18.87M |
| Gross Profit | -30.91M | -96.43M | -- | -- | -18.87M |
| SG&A Expenses | 9.14M | 9.13M | 7.86M | 8.33M | 7.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.05M | 39.90M | 35.18M | 27.79M | 26.86M |
| Operating Income | -40.05M | -39.90M | -35.18M | -27.79M | -26.86M |
| Income Before Tax | -39.28M | -42.60M | -32.73M | -25.07M | -24.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.28M | -42.60M | -32.73M | -25.07M | -24.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.28M | -42.60M | -32.73M | -25.07M | -24.30M |
| EBIT | -40.05M | -39.90M | -35.18M | -27.79M | -26.86M |
| EBITDA | -39.65M | -39.41M | -34.78M | -26.55M | -26.54M |
| EPS Basic | -0.59 | -1.00 | -0.79 | -0.61 | -0.64 |
| Normalized Basic EPS | -0.37 | -0.62 | -0.49 | -0.38 | -0.40 |
| EPS Diluted | -0.59 | -1.00 | -0.79 | -0.61 | -0.64 |
| Normalized Diluted EPS | -0.37 | -0.62 | -0.49 | -0.38 | -0.40 |
| Average Basic Shares Outstanding | 66.34M | 42.71M | 41.44M | 40.93M | 38.16M |
| Average Diluted Shares Outstanding | 66.34M | 42.71M | 41.44M | 40.93M | 38.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |